Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up

Buraa Kubaisi,1,2 Arash Maleki,1,2 Aseef Ahmed,1,2 Neel Lamba,1,2 Haitham Sahawneh,1,2 Andrew Stephenson,1,2 Alyssa Montieth,1,2 Shobha Topgi,3 C Stephen Foster1,2,4 1Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA; 2Ocular Immunology & Uveitis Foundation, Waltham, MA,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kubaisi B, Maleki A, Ahmed A, Lamba N, Sahawneh H, Stephenson A, Montieth A, Topgi S, Foster CS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Uveitis Glaucoma Ahmed glaucoma valve Fluocinolone Acetonide intravitreal implant Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/74a25a9e48184565912b040fc3102feb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74a25a9e48184565912b040fc3102feb
record_format	dspace
spelling	oai:doaj.org-article:74a25a9e48184565912b040fc3102feb2021-12-02T03:03:59ZAhmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up1177-5483https://doaj.org/article/74a25a9e48184565912b040fc3102feb2018-05-01T00:00:00Zhttps://www.dovepress.com/ahmed-glaucoma-valve-in-uveitic-patients-with-fluocinolone-acetonide-i-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Buraa Kubaisi,1,2 Arash Maleki,1,2 Aseef Ahmed,1,2 Neel Lamba,1,2 Haitham Sahawneh,1,2 Andrew Stephenson,1,2 Alyssa Montieth,1,2 Shobha Topgi,3 C Stephen Foster1,2,4 1Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA; 2Ocular Immunology & Uveitis Foundation, Waltham, MA, USA; 3The State University of New York Downstate, Brooklyn, NY, USA; 4Harvard Medical School, Boston, MA, USA Purpose: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) in eyes with noninfectious uveitis that had fluocinolone acetonide intravitreal implant (Retisert™)-induced glaucoma. Methods: This retrospective study reviewed the safety and efficacy of AGV implantation in patients with persistently elevated intraocular pressure (IOP) after implantation of a fluocinolone acetonide intravitreal implant at the Massachusetts Eye Research and Surgery Institution between August 2006 and November 2015. Results: Nine patients with 10 uveitic eyes were included in this study, none of which had preexisting glaucoma in the study eye. Mean patient age was 42 years; 6 patients were female and 3 were male. Baseline mean IOP was 30.6 mmHg prior to AGV placement while mean IOP-lowering medications were 2.9. In the treatment groups, there was a statistically significant reduction in post-AGV IOP. IOP was lowest at 1-week after AGV implantation (9.0 mmHg). Nine out of 10 eyes achieved an IOP below target value of 22 mmHg and/or a 20% reduction in IOP from baseline 1 month and 1 year following AGV placement. All other postoperative time points showed all 10 eyes reaching this goal. A statistically significant decrease in IOP-lowering medication was seen at the 1-week, 1-month, and 3-year time points compared to baseline, while a statistically significant increase was seen at the 3-month, 6-month, and 2-year post-AGV time points. No significant change in retinal nerve thickness or visual field analysis was found. Conclusion: AGV is an effective and safe method of treatment in fluocinolone acetonide intravitreal implant-induced glaucoma. High survival rate is expected for at least 3 years. Keywords: uveitis, glaucoma, Ahmed glaucoma valve, fluocinolone acetonide intravitreal implant, ocular inflammationKubaisi BMaleki AAhmed ALamba NSahawneh HStephenson AMontieth ATopgi SFoster CSDove Medical PressarticleUveitisGlaucomaAhmed glaucoma valveFluocinolone Acetonide intravitreal implantOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 799-804 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Uveitis Glaucoma Ahmed glaucoma valve Fluocinolone Acetonide intravitreal implant Ophthalmology RE1-994
spellingShingle	Uveitis Glaucoma Ahmed glaucoma valve Fluocinolone Acetonide intravitreal implant Ophthalmology RE1-994 Kubaisi B Maleki A Ahmed A Lamba N Sahawneh H Stephenson A Montieth A Topgi S Foster CS Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
description	Buraa Kubaisi,1,2 Arash Maleki,1,2 Aseef Ahmed,1,2 Neel Lamba,1,2 Haitham Sahawneh,1,2 Andrew Stephenson,1,2 Alyssa Montieth,1,2 Shobha Topgi,3 C Stephen Foster1,2,4 1Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA; 2Ocular Immunology & Uveitis Foundation, Waltham, MA, USA; 3The State University of New York Downstate, Brooklyn, NY, USA; 4Harvard Medical School, Boston, MA, USA Purpose: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) in eyes with noninfectious uveitis that had fluocinolone acetonide intravitreal implant (Retisert™)-induced glaucoma. Methods: This retrospective study reviewed the safety and efficacy of AGV implantation in patients with persistently elevated intraocular pressure (IOP) after implantation of a fluocinolone acetonide intravitreal implant at the Massachusetts Eye Research and Surgery Institution between August 2006 and November 2015. Results: Nine patients with 10 uveitic eyes were included in this study, none of which had preexisting glaucoma in the study eye. Mean patient age was 42 years; 6 patients were female and 3 were male. Baseline mean IOP was 30.6 mmHg prior to AGV placement while mean IOP-lowering medications were 2.9. In the treatment groups, there was a statistically significant reduction in post-AGV IOP. IOP was lowest at 1-week after AGV implantation (9.0 mmHg). Nine out of 10 eyes achieved an IOP below target value of 22 mmHg and/or a 20% reduction in IOP from baseline 1 month and 1 year following AGV placement. All other postoperative time points showed all 10 eyes reaching this goal. A statistically significant decrease in IOP-lowering medication was seen at the 1-week, 1-month, and 3-year time points compared to baseline, while a statistically significant increase was seen at the 3-month, 6-month, and 2-year post-AGV time points. No significant change in retinal nerve thickness or visual field analysis was found. Conclusion: AGV is an effective and safe method of treatment in fluocinolone acetonide intravitreal implant-induced glaucoma. High survival rate is expected for at least 3 years. Keywords: uveitis, glaucoma, Ahmed glaucoma valve, fluocinolone acetonide intravitreal implant, ocular inflammation
format	article
author	Kubaisi B Maleki A Ahmed A Lamba N Sahawneh H Stephenson A Montieth A Topgi S Foster CS
author_facet	Kubaisi B Maleki A Ahmed A Lamba N Sahawneh H Stephenson A Montieth A Topgi S Foster CS
author_sort	Kubaisi B
title	Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
title_short	Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
title_full	Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
title_fullStr	Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
title_full_unstemmed	Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
title_sort	ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/74a25a9e48184565912b040fc3102feb
work_keys_str_mv	AT kubaisib ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT malekia ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT ahmeda ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT lamban ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT sahawnehh ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT stephensona ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT montietha ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT topgis ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup AT fostercs ahmedglaucomavalveinuveiticpatientswithfluocinoloneacetonideimplantinducedglaucoma3yearfollowup
_version_	1718401990179946496

Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up

Ejemplares similares